The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

Size: px
Start display at page:

Download "The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not"

Transcription

1 The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product. Before prescribing any product mentioned in this Register, healthcare professionals should consult prescribing information for the product approved in their country. Study No.: HZC12871 Title: HZC12871: A 52-Week Efficacy And Safety Study To Compare The Effect Of Three Dosage Strengths Of Fluticasone Furoate/GW Inhalation Powder With GW On The Annual Rate Of Exacerbations In Subjects With Chronic Obstructive Pulmonary Disease Rationale: This study was conducted to provide data on the safety and efficacy of inhaled doses of fluticasone furoate/vilanterol () versus administered once-daily (OD) from a Novel Dry Powder Inhaler (NDPI) on the annual rate of moderate and severe exacerbations in subjects with COPD over a 52- week treatment period. Phase: III Study Period: SEP29 31OCT211 Study Design: This was a multicenter, randomized, double-blind, parallel-group design evaluating the effects of OD in the morning (AM) treatment with three dosage strengths of (5/, 1/ and 2/ mcg) versus one dosage strength of ( mcg) in subjects with COPD. Following screening to assess eligibility and a 4-week run-in period during which all subjects received open-label fluticasone propionate / salmeterol /5 mcg (FP/SAL /5) twice daily (BD) to establish a stable baseline, subjects were randomized (1:1:1:1) to one of the double-blind treatments ( 5/, 1/, 2/, or ), delivered via NDPI OD in the AM for 52 weeks. The randomisation was stratified based on smoking status. Except for short acting anticholinergics, subjects discontinued their use of previous COPD medications prior to run-in. Subjects attended clinic visits at screening, randomization, and after 2, 4, 8, 12, 2, 28, 36, 44, and 52 weeks of treatment. A safety follow-up phone contact occurred 1 week after completing either randomized treatment or an early withdrawal visit. Subjects were provided with inhaled albuterol/salbutamol for use as rescue medication throughout the study. The total duration of the study was approximately 57 weeks (including the 4-week run-in period, 52-week treatment period and the 1-week follow-up period) for each completed subject. Centres: 167 centers in 15 countries enrolled at least one subject Indication: COPD Treatment: During Run-in, subjects received open-label FP/SAL /5 BD. During the 52-week treatment period, all blinded dry powder formulations of and were administered via NDPI OD in the AM. Objectives: The primary objective of this study was to evaluate safety and efficacy of 5/ mcg, 1/ mcg and 2/ mcg versus mcg on the annual rate of moderate and severe exacerbations in subjects with COPD over a 52-week treatment period. This study evaluated the contribution of the ICS component on reducing the annual rate of moderate-severe exacerbations when used in combination with a fixed dose of the LABA in subjects with COPD. Primary Outcome/Efficacy Variable: Annual rate of moderate and severe exacerbations. Secondary Outcome/Efficacy Variable(s): Time to first moderate or severe exacerbation; Annual rate of exacerbations requiring systemic/oral corticosteroids; Change from baseline in trough FEV 1 at Visit 11. Statistical Methods: A total of 2631 subjects were screened with the aim of achieving evaluable data from 156 randomized subjects (39 subjects per treatment arm). This sample size was based on the primary endpoint, the annual rate of moderate and severe exacerbations and on the comparison of each combination arm compared with the -alone arm. The annual rate of moderate and severe exacerbations in the treatment arm was assumed to be 1.4 based on estimates of 1.4 to 1.59 from the salmeterol arms of fluticasone propionate/salmeterol (FP/SAL) combination studies. Estimates of the dispersion parameter in previous FP/SAL studies have been.7;.46;.48 and.47. As the current study was a multicenter, international study the higher estimate of dispersion was used in the sample size calculation. This study with 39 evaluable subjects per arm had 9% power to detect a % reduction in the annual rate of moderate and severe exacerbations on a combination arm compared with the -alone arm. Calculations were based on a Negative Binomial regression and used a two-sided 5% significance level. In 1

2 order to account for multiplicity across treatment comparisons and key endpoints, a step-down testing procedure was employed, whereby inference for the primary efficacy endpoint for the 1/ combination strength versus was dependent upon statistical significance at the 5% level having first been achieved for the primary efficacy endpoint for 2/ versus comparison. Similarly, inference for the primary efficacy endpoint for the 5/ versus comparison was dependent upon statistical significance having first been achieved for the primary efficacy endpoint for 1/ versus comparison. For a given combination strength, the secondary endpoints were nested under the primary endpoint. Secondary efficacy endpoints were (in order): time to first moderate or severe exacerbation, the annual rate of exacerbations requiring treatment with systemic/oral corticosteroids and trough FEV 1 at 52 weeks. Hence, in order to make inferences on the secondary endpoints at a given strength, statistical significance at the 5% level had to have been demonstrated for the primary efficacy endpoint for that combination strength. A 2-sided 5% risk associated with incorrectly rejecting the null hypothesis (significance level) was considered acceptable for this study. The ITT population, defined as all subjects who had been randomized to and received at least one dose of randomized double blind study medication in the treatment period, was the population of primary interest for all efficacy and safety endpoints. Study Population: Number of Subjects: Planned, N Total 156 randomized subjects (39 subjects per treatment arm) Randomised, N 1626 Completed, n (%) (Subjects were considered to have 1222 (75) completed the study if they completed the treatment period and a safety follow-up phone contact 1 week later) Completed the treatment period (Subjects were considered to have completed the treatment period if they attended the last treatment visit (Visit 11). 123 (76) Withdrawn 4 () Primary /Sub-reason for withdrawal, n (%) 5/ 1/ 2/ N=49 N=48 N=43 N=42 Adverse Event 22 (5) (6) 29 (7) 31 (8) Withdrew consent 34 (8) 18 (4) 17 (4) 22 (5) Lack of efficacy 24 (6) 16 (4) 11 (3) 18 (4) Exacerbation 15 (4) 1 (2) 4 (<1) 13 (3) Withdrawn for other reasons 35 (9) 34 (8) 34 (8) 3 (7) Demographics, n (%) N (ITT) Gender n Females Males Age n Mean Age, years SD Race n White African American/ African (42) 239 (58) (81) 9 (2) (4) 245 (6) (82) 8 (2) (43) 231 (57) (82) 6 (1) (38) 249 (62) (81) 9 (2) 2

3 Heritage Asian Other (includes the following races and racial combinations: American Indian or Alaska Native; American Indian or Alaska Native & White; Asian & White) COPD history at screening, n (%) Duration of COPD n <1 year >=1 to <5 years >=5 to <1 years >=1 to <15 years >=15 to <2 years >=2 to < years >= years COPD type (subjects could select 'Chronic bronchitis', 'Emphysema' or both for COPD type) n Chronic bronchitis Emphysema 39 (1) 29 (7) 49 2 (5) 136 (33) 134 (33) 68 (17) 24 (6) 2 (5) 7 (2) (64) 229 (56) 37 (9) 29 (7) (7) 167 (41) 12 (29) 5 (12) 2 (5) 13 (3) 11 (3) 45 7 (63) 238 (59) 37 (9) 28 (7) (6) 134 (33) 123 (31) 62 (15) 36 (9) 14 (3) 11 (3) (66) 228 (57) 41 (1) 27 (7) (4) 156 (39) 132 (33) 54 (13) 24 (6) 12 (3) 6 (1) (66) 243 (61) 3

4 Screening lung function All results were taken at the Screening/Rescreening Visit except Baseline FEV1 which was taken at pre-dose Day 1. Measure N=49 5/ N=48 1/ N=43 2/ N=42 Pre-bronchodilator FEV 1 (L) Post-bronchodilator FEV 1 (L) Percent predicted post-bronchodilator FEV 1 (%) Post-bronchodilator FEV 1 /FVC (%) Percent reversibility FEV 1 (%) FEV 1 reversibility (ml) Reversibility at Screening Baseline FEV 1 (L) Measured at pre-dose Day 1 n Mean SD Min-Max n Mean SD Min-Max n Mean SD Min-Max n Mean SD Min-Max n Mean SD Min-Max n Mean SD Min-Max n Reversible 1 (31) 116 (29) 121 (3) 16 (27) Non- Reversible 282 (69) 287 (71) 279 (7) 29 (73) n Mean SD Min-Max

5 Primary Efficacy Results: Annual rate of moderate and severe exacerbations N=49 5/ N=48 1/ N=43 2/ N=42 n LS mean annual rate Column vs. Ratio % CI (.72, 1.6) (.54,.81) (.7, 1.4) p-value.181 <.1.19 Percent Reduction % CI (-6, 28) (19, 46) (-4, 3) Analysis performed using a negative binomial regression model with covariates of treatment, smoking status at screening (stratum), baseline disease severity (pre-dose Day 1 % predicted FEV1) and center grouping and with logarithm of time on treatment as an offset variable. Secondary Outcome Variable(s): Time to first moderate or severe exacerbation N=49 5/ N=48 1/ N=43 2/ N=42 n Column vs. Hazard Ratio % CI (.76, 1.13) (.59,.89) (.69, 1.4) Hazard ratios, CIs and p-values are from a Cox proportional hazards model with covariates of treatment, smoking status at screening (stratum), baseline disease severity (pre-dose Day 1 % predicted FEV1) and center grouping. Annual rate of exacerbations requiring systemic/oral corticosteroids N=49 5/ N=48 1/ N=43 2/ N=42 n LS mean annual rate Column vs. Ratio % CI (.67, 1.5) (.49,.78) (.64, 1.1) Percent reduction % CI (-5, 33) (22, 51) (-1, 36) Analysis performed using a negative binomial regression model with covariates of treatment, smoking status at screening (stratum), baseline disease severity (pre-dose Day 1 % predicted FEV1) and center grouping and with logarithm of time on treatment as an offset variable. 5

6 Change from baseline in trough FEV 1 at Visit 11. N=49 5/ N=48 1/ N=43 2/ N=42 n a n b LS Mean (SE) 1.18 (.114) 1.22 (.112) (.112) (.114) LS Mean Change (SE) -.4 (.114). (.112).18 (.112).24 (.114) Column vs. Difference % CI (.9,.72) (.27,.9) (.33,.96) Analysis performed using a repeated measures model with covariates of treatment, smoking status at screening (stratum), baseline (pre-dose Day 1), center grouping, Week, Week by baseline and Week by treatment interactions. a. Number of subjects with analyzable data for one or more time points. b. Number of subjects with analyzable data at the given time point. Safety Results: An adverse event (AE) was defined as any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs were collected from the start of open-label ADVAIR DISKUS /5 run-in period (Visit 1) and until the follow up contact. A serious adverse event (SAE) was defined as any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required hospitalisation or prolongation of existing hospitalisation (complications that occurred during hospitalisation were AEs; complications that prolonged hospitalisation or fulfilled any other serious criteria, were an SAE), resulted in disability/incapacity to conduct normal life functions, or was a congenital anomaly/birth defect. SAEs were collected over the same time period as stated above for AEs. However, any SAEs assessed as related to study participation (e.g., investigational product, protocol-mandated procedures, invasive tests, or change in existing therapy) or related to a GSK concomitant medication, were recorded from the time a subject consents to participate in the study up to and including any follow up contact. Overview of Adverse Events n (%) N=49 5/ N=48 1/ N=43 2/ N=42 During run-in 77 (19) 78 (19) 91 (23) 86 (21) On-treatment 281 (69) 34 (75) 31 (75) 288 (72) Post-treatment 14 (3) 22 (5) 12 (3) 12 (3) On-treatment drug-related 5 (12) 85 (21) 64 (16) 6 (15) Post-treatment drug-related 5 (1) 3 (<1) Leading to permanent discontinuation of study drug or withdrawal from study a 22 (5) 26 (6) 29 (7) 3 (7) a. Includes both on-treatment and post-treatment adverse events 6

7 Most Frequent Adverse Events On-Therapy Preferred term, n (%) N=49 5/ N=48 1/ N=43 2/ N= (69) 34 (75) 31 (75) 288 (72) Nasopharyngitis 54 (13) 58 (14) 6 (15) 76 (19) Upper respiratory tract infection 47 (11) 47 (12) 51 (13) 39 (1) Oral candidiasis 21 (5) 39 (1) 34 (8) 36 (9) Headache 3 (7) 27 (7) (6) 34 (8) COPD 28 (7) 27 (7) 26 (6) 3 (7) Adverse Events of Special Interest On-Therapy The incidence of pneumonia reported as an AE (grouped preferred terms indicative of pneumonia) was 4% in the mcg group vs. 6% to 8% of subjects in the three groups. Overview of Serious Adverse Events n (%) N=49 5/ N=48 1/ N=43 2/ N=42 On-treatment 6 (15) 65 (16) 56 (14) 63 (16) Post-treatment 4 (<1) 6 (1) 5 (1) On-treatment drug-related 5 (1) 7 (2) Post-treatment drug-related On- treatment fatal 4 (<1) 7 (2) 5 (1) 13 (3) Post-treatment fatal 3 (<1) 3 (<1) On- and post-treatment drug-related fatal SAEs 7

8 Summary of On-Treatment Serious Adverse Events by System Organ Class n (%) N=49 5/ N=48 1/ N=43 2/ N=42 Any serious event 6 (15) 65 (16) 56 (14) 63 (16) Respiratory, thoracic and mediastinal 3 (7) 31 (8) 3 (7) 33 (8) disorders Infections and infestations 1 (2) 19 (5) 21 (5) 21 (5) Cardiac disorders 1 (2) 7 (2) 6 (1) 5 (1) Gastrointestinal disorders 5 (1) 5 (1) 7 (2) Neoplasms benign, malignant, and 6 (1) 3 (<1) 4 (<1) unspecified (including cysts and polyps) Nervous system disorders 4 (<1) 3 (<1) 5 (1) Metabolism and nutrition disorders 3 (<1) Musculoskeletal and connective tissue 3 (<1) 3 (<1) disorders Vascular disorders 3 (<1) Injury, poisoning and procedural 5 (1) complications General disorders and administration 3 (<1) site conditions Renal and urinary disorders 3 (<1) Hepatobiliary disorders Blood and lymphatic disorders Psychiatric disorders Reproductive system and breast disorders Eye disorders Immune system disorders 8

9 On-treatment Serious Adverse Events considered by the investigator to be related to study medication System Organ Class Preferred term, n (%) 5/ 1/ 2/ N=42 N=49 N=48 N=43 5 (1) 7 (2) Respiratory, thoracic and mediastinal disorders 5 (1) COPD 4 (<1) Acute respiratory failure Asthma Bronchitis chronic Infections and infestations 5 (1) Pneumonia 4 (<1) Lung abscess Cardiac disorders Palpitations General disorders and administration site conditions Non-cardiac chest pain Neoplasms benign, malignant, and unspecified (including cysts and polyps) Metastatic carcinoma of the bladder 9

10 Fatal Serious Adverse Events (during treatment period and post treatment) System Organ Class Preferred term, n (%) N=49 5/ N=48 1/ N=43 2/ N=42 7 (2) 9 (2) 6 (1) 13 (3) Cardiac disorders Myocardial infarction Acute coronary syndrome Angina unstable Arrhythmia Cardiac arrest Cardiac failure Cardio-respiratory arrest Cardiopulmonary failure Coronary artery thrombosis Respiratory, thoracic and mediastinal disorders Chronic obstructive pulmonary disease Acute respiratory failure Respiratory failure Infections and infestations Pneumonia Sepsis Septic shock Urinary tract infection bacterial 4 (<1) Neoplasms benign, malignant and unspecified (incl cysts and polyps) Acute lymphocytic leukaemia Diffuse large B-cell lymphoma Pancreatic carcinoma metastatic Vascular disorders Aortic aneurysm rupture Hypertension Shock haemorrhagic Gastrointestinal disorders Abdominal pain Abdominal pain lower General disorders and administration site conditions Death Nervous system disorders Cerebrovascular accident Loss of consciousness Musculoskeletal and connective tissue disorders Intervertebral disc protrusion 3 (<1) 5 (1) 4 (<1) 6 (1) 6 (1) 1

11 Conclusion: Once-daily treatment in the morning with 5/, 1/, or 2/ decreased the annual rate of moderate and severe exacerbations with the greatest magnitude of effect noted in the 1/ group (34% reduction with a p<.1). Similar results were observed for secondary endpoint measures (time to first moderate or severe exacerbation, and the annual rate of exacerbations requiring systemic/oral corticosteroids). All strengths of provided changes in trough FEV 1 measures of lung function of 41 to 64 ml compared with at 52 weeks. There was an increased incidence of pneumonia and candidiasis; fatal events of pneumonia were reported for no subjects in the, 5/, and 1/ groups and six subjects in the 2/ group (plus one additional subject with a fatal SAE of COPD exacerbation that was recorded as a fatal pneumonia on the pneumonia ecrf page). 11

Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: Secondary Outcome/Efficacy Variable(s): Statistical Methods:

Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: Secondary Outcome/Efficacy Variable(s): Statistical Methods: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Co-Primary Outcomes/Efficacy Variables:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Co-Primary Outcomes/Efficacy Variables: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

UMEC/VI vs. UMEC in subjects who responded to UMEC UMEC/VI vs. VI in subjects who responded to VI

UMEC/VI vs. UMEC in subjects who responded to UMEC UMEC/VI vs. VI in subjects who responded to VI The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: SFCA3007 Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial Evaluating the Safety and Efficacy of the DISKUS

Study No.: SFCA3007 Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial Evaluating the Safety and Efficacy of the DISKUS Study No.: A3007 Title: A Randomized, Double-Blind, -Controlled, Parallel-Group Trial Evaluating the Safety and Efficacy of the DISKUS Formulations of Salmeterol (SAL) 50mcg BID and Fluticasone Propionate

More information

Clinical Trial Results Database Page 1

Clinical Trial Results Database Page 1 Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major Depressive Disorder (MDD) Approved Indication Treatment of major depressive

More information

Full Novartis CTRD Results Template

Full Novartis CTRD Results Template Full Novartis CTRD Results Template Sponsor Novartis Generic Drug Name vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Protocol Number CLAF237A23138E1 Title A

More information

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective:

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective: GSK Medicine: abacavir (ABC)/dolutegravir (DTG)/lamivudine (3TC) Study Number: 201147 Title: A IIIb, randomized, open-label study of the safety, efficacy, and tolerability of switching to a fixed-dose

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Full Novartis CTRD Results Template

Full Novartis CTRD Results Template Full Novartis CTRD Results Template Sponsor Novartis Generic Drug Name vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Protocol Number CLAF237A23137E1 Title A

More information

Study No.: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives : Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives : Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Blood Eosinophils and Response to Maintenance COPD Treatment: Data from the FLAME Trial. Online Data Supplement

Blood Eosinophils and Response to Maintenance COPD Treatment: Data from the FLAME Trial. Online Data Supplement Blood Eosinophils and Response to Maintenance COPD Treatment: Data from the FLAME Trial Nicolas Roche, Kenneth R. Chapman, Claus F. Vogelmeier, Felix JF Herth, Chau Thach, Robert Fogel, Petter Olsson,

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Secondary Outcome/Efficacy Variable(s):

Secondary Outcome/Efficacy Variable(s): The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment:

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Sponsor. Novartis. Generic Drug Name. Vildagliptin. Therapeutic Area of Trial. Type 2 diabetes. Approved Indication. Type 2 diabetes.

Sponsor. Novartis. Generic Drug Name. Vildagliptin. Therapeutic Area of Trial. Type 2 diabetes. Approved Indication. Type 2 diabetes. Sponsor Page 1 Novartis Generic Drug Name Vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Study Number CLAF237A2308 Title A multicenter, randomized, double-blind,

More information

Sponsor Novartis. Generic Drug Name Vildagliptin/Metformin. Therapeutic Area of Trial Type 2 diabetes. Approved Indication Type 2 diabetes

Sponsor Novartis. Generic Drug Name Vildagliptin/Metformin. Therapeutic Area of Trial Type 2 diabetes. Approved Indication Type 2 diabetes Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin/Metformin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Study Number CLMF237A2309

More information

SYNOPSIS. Study center(s) This study was conducted in the United States (128 centers).

SYNOPSIS. Study center(s) This study was conducted in the United States (128 centers). Drug product: Drug substance(s): Document No.: Edition No.: Study code: Date: SYMBICORT pmdi 160/4.5 µg Budesonide/formoterol SD-039-0725 17 February 2005 SYNOPSIS A Twelve-Week, Randomized, Double-blind,

More information

Study No: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis

Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis A service of the U.S. National Institutes of Health Trial record 1 of 1 for: CZOL446H2409 Previous Study Return to List Next Study Efficacy Study of Zoledronic Acid and Combination Therapy in Women With

More information

Study No.: SAM40012 Title: A multicentre, randomised, double-blind, double-dummy, parallel group comparison of three treatments : 1)

Study No.: SAM40012 Title: A multicentre, randomised, double-blind, double-dummy, parallel group comparison of three treatments : 1) Study No.: SAM40012 Title: A multicentre, randomised, double-blind, double-dummy, parallel group comparison of three treatments : 1) salmeterol/fluticasone propionate () (mcg strength) bd via DISKUS/ACCUHALER

More information

Study No.: LOV Title: Rationale: Phase: IIB Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary-

Study No.: LOV Title: Rationale: Phase: IIB Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary- The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Sponsor. Novartis Pharmaceuticals Corporation Generic Drug Name. Agomelatine Therapeutic Area of Trial. Major depressive disorder Approved Indication

Sponsor. Novartis Pharmaceuticals Corporation Generic Drug Name. Agomelatine Therapeutic Area of Trial. Major depressive disorder Approved Indication Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major depressive disorder Approved Indication Investigational drug Study

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

SYNOPSIS A two-stage randomized, open-label, parallel group, phase III, multicenter, 7-month study to assess the efficacy and safety of SYMBICORT

SYNOPSIS A two-stage randomized, open-label, parallel group, phase III, multicenter, 7-month study to assess the efficacy and safety of SYMBICORT Drug product: Drug substance(s): Edition No.: Study code: SYMBICORT pmdi 160/4.5 g Budesonide/formoterol D5896C00005 Date: 8 May 2006 SYNOPSIS A two-stage randomized, open-label, parallel group, phase

More information

Not available 100/6mcg 2 BD formoterol (Fostair MDI) 100/6mcg 33

Not available 100/6mcg 2 BD formoterol (Fostair MDI) 100/6mcg 33 COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP FLUTICASONE FUROATE/VILANTEROL COMBINATION INHALER - ASTHMA Policy agreed by Vale of York CCG (date) Drug, Treatment, Device name Fluticasone

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis

More information

Supplementary appendix

Supplementary appendix Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Calverley P M A, Anzueto A R, Carter K, et

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Sponsor Novartis Pharmaceuticals

Sponsor Novartis Pharmaceuticals Sponsor Novartis Pharmaceuticals Generic Drug Name Indacaterol maleate-glycopyrronium bromide Trial Indication(s) Chronic obstructive pulmonary disease Protocol Number CQVA149A2339 Protocol Title A placebo

More information

Sponsor / Company: Sanofi Drug substance(s): Insulin Glargine. According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1

Sponsor / Company: Sanofi Drug substance(s): Insulin Glargine. According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1 These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):

More information

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

TORCH: Salmeterol and Fluticasone Propionate and Survival in COPD

TORCH: Salmeterol and Fluticasone Propionate and Survival in COPD TORCH: and Propionate and Survival in COPD April 19, 2007 Justin Lee Pharmacy Resident University Health Network Outline Overview of COPD Pathophysiology Pharmacological Treatment Overview of the TORCH

More information

Relvar Ellipta (fluticasone furoate/vilanterol [as trifenatate]) for the treatment of patients with asthma

Relvar Ellipta (fluticasone furoate/vilanterol [as trifenatate]) for the treatment of patients with asthma Relvar Ellipta (fluticasone furoate/vilanterol [as trifenatate]) for the treatment of patients with asthma Evidence Summary to support formulary decision making and guideline development Prescribing and

More information

ClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: 01/19/2016. ClinicalTrials.gov ID: NCT

ClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: 01/19/2016. ClinicalTrials.gov ID: NCT ClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: 01/19/2016 ClinicalTrials.gov ID: NCT00595413 Study Identification Unique Protocol ID: 27905 Brief Title: Atacicept

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Treatment A Placebo to match COREG CR 20 mg OD + Lisinopril 10 mg OD (Days 1-7) Placebo to match COREG CR 40 mg OD + Lisinopril 10 mg OD (Days 8-14)

Treatment A Placebo to match COREG CR 20 mg OD + Lisinopril 10 mg OD (Days 1-7) Placebo to match COREG CR 40 mg OD + Lisinopril 10 mg OD (Days 8-14) The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

SYNOPSIS. First subject enrolled 15 August 2003 Therapeutic confirmatory (III) Last subject completed 03 February 2005

SYNOPSIS. First subject enrolled 15 August 2003 Therapeutic confirmatory (III) Last subject completed 03 February 2005 Drug product: SYMBICORT pmdi 160/4.5 μg Drug substance(s): Budesonide/formoterol Study code: SD-039-0728 Edition No.: FINAL Date: 27 February 2006 SYNOPSIS A 52-week, randomized, double-blind, single-dummy,

More information

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

ClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: 10/11/2013. ClinicalTrials.gov ID: NCT

ClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: 10/11/2013. ClinicalTrials.gov ID: NCT ClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: 10/11/2013 ClinicalTrials.gov ID: NCT00168454 Study Identification Unique Protocol ID: 191622-077 Brief Title: A

More information

This was a randomized, double-blind, placebo-controlled, fixed-dose, parallel-group study.

This was a randomized, double-blind, placebo-controlled, fixed-dose, parallel-group study. The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period Study Design: Group 1 (Test Group) Group 2 (Reference group):

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period Study Design: Group 1 (Test Group) Group 2 (Reference group): The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

ClinicalTrials.gov "Basic Results" Data Element Definitions (DRAFT)

ClinicalTrials.gov Basic Results Data Element Definitions (DRAFT) ClinicalTrials.gov "Basic Results" Data Element Definitions (DRAFT) January 9, 2009 * Required by ClinicalTrials.gov [*] Conditionally required by ClinicalTrials.gov (FDAAA) May be required to comply with

More information

Clinical Trial Results Database Page 1

Clinical Trial Results Database Page 1 Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Therapeutic Area of Trial L-dopa induced dyskinesias in Parkinson s disease (PD-LID) Approved Indication Not approved yet for any

More information

Study No.:MPX Title: Rationale: Phase: IIB Study Period: Study Design: Centres: Indication: Treatment: Objectives:

Study No.:MPX Title: Rationale: Phase: IIB Study Period: Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

ClinialTrials.gov Identifier: sanofi-aventis. Sponsor/company: 07/November/2008

ClinialTrials.gov Identifier: sanofi-aventis. Sponsor/company: 07/November/2008 These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov

More information

Sponsor. Generic Drug Name. Trial Indications. Protocol Number. Protocol Title. Clinical Trial Phase. Study Start/End Dates. Reason for Termination

Sponsor. Generic Drug Name. Trial Indications. Protocol Number. Protocol Title. Clinical Trial Phase. Study Start/End Dates. Reason for Termination Sponsor Alcon Research, Ltd. Generic Drug Name Travoprost/timolol maleate Trial Indications Open-angle glaucoma or ocular hypertension Protocol Number C-09-007 Protocol Title An Evaluation of Patient Reported

More information

Lead team presentation: Roflumilast for treating chronic obstructive pulmonary disease [ID984]

Lead team presentation: Roflumilast for treating chronic obstructive pulmonary disease [ID984] Lead team presentation: Roflumilast for treating chronic obstructive pulmonary disease [ID984] 1 st Appraisal Committee meeting Background & Clinical Effectiveness John McMurray 11 th January 2016 For

More information

Summary of the risk management plan (RMP) for Duaklir Genuair (aclidinium / formoterol fumarate dihydrate)

Summary of the risk management plan (RMP) for Duaklir Genuair (aclidinium / formoterol fumarate dihydrate) EMA/605453/2014 Summary of the risk management plan (RMP) for Duaklir Genuair (aclidinium / formoterol fumarate dihydrate) This is a summary of the risk management plan (RMP) for Duaklir Genuair, which

More information

PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN

PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN VI.1 Summary of risk management plan for RELVAR ELLIPTA (fluticasone furoate/vilanterol) This is a summary of the risk management plan (RMP) for RELVAR ELLIPTA.

More information

Clinical Trial Synopsis TL-OPI-525, NCT#

Clinical Trial Synopsis TL-OPI-525, NCT# Clinical Trial Synopsis, NCT#00762736 Title of Study: A Phase II, Double-Blind, Randomized, Placebo-Controlled, Proof-of-Concept Study of the Efficacy, Safety, and Tolerability of Pioglitazone HCl (ACTOS

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Vestbo J, Leather D, Diar Bakerly N, et al. Effectiveness of

More information

Clinical Trial Results Summary Study EN3409-BUP-305

Clinical Trial Results Summary Study EN3409-BUP-305 Title of Study: A 52-Week, Open-Label, Long-Term Treatment Evaluation of the Safety and Efficacy of BEMA Buprenorphine in Subjects with Moderate to Severe Chronic Pain Coordinating Investigator: Martin

More information

Outcomes: Initially, our primary definitions of pneumonia was severe pneumonia, where the subject was hospitalized

Outcomes: Initially, our primary definitions of pneumonia was severe pneumonia, where the subject was hospitalized The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

GSK Medicine Study Number: Title: Rationale Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

GSK Medicine Study Number: Title: Rationale Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and nonapproved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

fluticasone furoate / vilanterol 92/22, 184/22 micrograms inhalation powder (Relvar Ellipta ) SMC No. (966/14) GlaxoSmithKline UK

fluticasone furoate / vilanterol 92/22, 184/22 micrograms inhalation powder (Relvar Ellipta ) SMC No. (966/14) GlaxoSmithKline UK fluticasone furoate / vilanterol 92/22, 184/22 micrograms inhalation powder (Relvar Ellipta ) SMC No. (966/14) GlaxoSmithKline UK 09 May 2014 The Scottish Medicines Consortium (SMC) has completed its assessment

More information

SYNOPSIS. Clinical Study Report IM Double-blind Period

SYNOPSIS. Clinical Study Report IM Double-blind Period Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Abatacept () Name of Active Ingredient: Abatacept () Individual Study Table Referring to the Dossier SYNOPSIS (For National Authority

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Sponsor Novartis. Generic Drug Name Pasireotide. Therapeutic Area of Trial Cushing s disease. Protocol Number CSOM230B2208E1

Sponsor Novartis. Generic Drug Name Pasireotide. Therapeutic Area of Trial Cushing s disease. Protocol Number CSOM230B2208E1 Sponsor Novartis Generic Drug Name Pasireotide Therapeutic Area of Trial Cushing s disease Protocol Number CSOM230B2208E1 Title Extension to a multicenter, open-label study to assess the safety and efficacy

More information

Sponsor Novartis. Generic Drug Name. NA (not existing yet) Therapeutic Area of Trial Parkinson s Disease L-dopa induced dyskinesia

Sponsor Novartis. Generic Drug Name. NA (not existing yet) Therapeutic Area of Trial Parkinson s Disease L-dopa induced dyskinesia Page 1 Sponsor Novartis Generic Drug Name NA (not existing yet) Therapeutic Area of Trial Parkinson s Disease L-dopa induced dyskinesia Approved Indication Investigational. Study Number CA2206 Title A

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: Study No.: 29060/717 Title: A Double-Blind, Placebo-Controlled, 3-Arm, Fixed-Dose Study of CR Intermittent Dosing (12.5 mg and 25 mg) for Premenstrual Dysphoric Disorder Rationale: In most trials investigating

More information

umeclidinium, 55 micrograms, powder for inhalation (Incruse ) SMC No. (1004/14) GlaxoSmithKline

umeclidinium, 55 micrograms, powder for inhalation (Incruse ) SMC No. (1004/14) GlaxoSmithKline umeclidinium, 55 micrograms, powder for inhalation (Incruse ) SMC No. (1004/14) GlaxoSmithKline 07 November 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product

More information

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis

More information

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Treatment B: FF (400 µg) and UMEC (250 µg)/vi(100 µg) The indicated dose is the total of four inhalations via the dry powder inhaler.

Treatment B: FF (400 µg) and UMEC (250 µg)/vi(100 µg) The indicated dose is the total of four inhalations via the dry powder inhaler. GSK Medicine:GSK573719 (Umeclidinium)+ GW6424 (Vilanterol) + GW685698 (Fluticasone furoate) Study Number: 200587 Title: An open label, randomised, four-period crossover, single dose study in healthy volunteers

More information

Evidence Summary to support COPD formulary decision making and guideline development

Evidence Summary to support COPD formulary decision making and guideline development Evidence Summary to support COPD formulary decision making and guideline development Prescribing and adverse event reporting information can be found on the final page of this document. Trelegy and Ellipta

More information

Utibron Neohaler. (indacaterol, glycopyrrolate) New Product Slideshow

Utibron Neohaler. (indacaterol, glycopyrrolate) New Product Slideshow Utibron Neohaler (indacaterol, glycopyrrolate) New Product Slideshow Introduction Brand name: Utibron Neohaler Generic name: Indacaterol, glycopyrrolate Pharmacological class: Long-acting beta2- agonist

More information

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Lind M, Polonsky W, Hirsch IB, et al. Effect of continuous glucose monitoring vs conventional therapy on glycemic control among patients type 1 diabetes treated multiple daily

More information

The population of subjects which was statistically analyzed was the Intent-to-Treat population

The population of subjects which was statistically analyzed was the Intent-to-Treat population Study No.: ARIB3003 (Year 1) Title: A Randomized, Double-Blind, Placebo-Controlled, Two-Year Parallel-Group Study of the Efficacy and Safety of GI198745 in the Treatment and Modification of Progression

More information

Study No Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable(s):

Study No Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable(s): Studies listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

Sponsor Novartis. Generic Drug Name. Valsartan and amlodipine Trial Indication(s) Hypertension Protocol Number CVAA489A2306 Protocol Title

Sponsor Novartis. Generic Drug Name. Valsartan and amlodipine Trial Indication(s) Hypertension Protocol Number CVAA489A2306 Protocol Title Sponsor Novartis Generic Drug Name Valsartan and amlodipine Trial Indication(s) Hypertension Protocol Number CVAA489A2306 Protocol Title A randomized, double-blind, multi-center, active-controlled, parallel

More information

Clinical Trial Results Database Page 1

Clinical Trial Results Database Page 1 Page 1 Sponsor Novartis UK Limited Generic Drug Name Letrozole/FEM345 Therapeutic Area of Trial Localized ER and/or PgR receptor positive breast cancer Study Number CFEM345EGB07 Protocol Title This study

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: TAG IDAG Objectives:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: TAG IDAG Objectives: The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

More information

aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A.

aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A. aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A. 05 October 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and

More information

SYNOPSIS 2/198 CSR_BDY-EFC5825-EN-E02. Name of company: TABULAR FORMAT (For National Authority Use only)

SYNOPSIS 2/198 CSR_BDY-EFC5825-EN-E02. Name of company: TABULAR FORMAT (For National Authority Use only) SYNOPSIS Title of the study: A randomized, double-blind, placebo-controlled, parallel-group, fixed-dose (rimonabant 20 mg) multicenter study of long-term glycemic control with rimonabant in treatment-naïve

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis

More information

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI.

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI. PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.

More information